267 related articles for article (PubMed ID: 36080255)
1. Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis.
Banerjee S; Lee S; Norman DD; Tigyi GJ
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080255
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
3. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
4. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Orosa B; García S; Conde C
Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
[TBL] [Abstract][Full Text] [Related]
5. Autotaxin-LPA axis regulates hMSC migration by adherent junction disruption and cytoskeletal rearrangement via LPAR1/3-dependent PKC/GSK3β/β-catenin and PKC/Rho GTPase pathways.
Ryu JM; Han HJ
Stem Cells; 2015 Mar; 33(3):819-32. PubMed ID: 25376707
[TBL] [Abstract][Full Text] [Related]
6. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
Budd DC; Qian Y
Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
[TBL] [Abstract][Full Text] [Related]
7. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B
Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
9. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.
Magkrioti C; Oikonomou N; Kaffe E; Mouratis MA; Xylourgidis N; Barbayianni I; Megadoukas P; Harokopos V; Valavanis C; Chun J; Kosma A; Stathopoulos GT; Bouros E; Bouros D; Syrigos K; Aidinis V
Cancer Res; 2018 Jul; 78(13):3634-3644. PubMed ID: 29724718
[TBL] [Abstract][Full Text] [Related]
10. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
[TBL] [Abstract][Full Text] [Related]
11. A defective lysophosphatidic acid-autophagy axis increases miscarriage risk by restricting decidual macrophage residence.
Yang HL; Lai ZZ; Shi JW; Zhou WJ; Mei J; Ye JF; Zhang T; Wang J; Zhao JY; Li DJ; Li MQ
Autophagy; 2022 Oct; 18(10):2459-2480. PubMed ID: 35220880
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8
Matas-Rico E; Frijlink E; van der Haar Àvila I; Menegakis A; van Zon M; Morris AJ; Koster J; Salgado-Polo F; de Kivit S; Lança T; Mazzocca A; Johnson Z; Haanen J; Schumacher TN; Perrakis A; Verbrugge I; van den Berg JH; Borst J; Moolenaar WH
Cell Rep; 2021 Nov; 37(7):110013. PubMed ID: 34788605
[TBL] [Abstract][Full Text] [Related]
13. The Expression Regulation and Biological Function of Autotaxin.
Zhang X; Li M; Yin N; Zhang J
Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish.
Lai SL; Yao WL; Tsao KC; Houben AJ; Albers HM; Ovaa H; Moolenaar WH; Lee SJ
Development; 2012 Dec; 139(23):4439-48. PubMed ID: 23095890
[TBL] [Abstract][Full Text] [Related]
15. MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia.
Plastira I; Bernhart E; Joshi L; Koyani CN; Strohmaier H; Reicher H; Malle E; Sattler W
J Neuroinflammation; 2020 Apr; 17(1):127. PubMed ID: 32326963
[TBL] [Abstract][Full Text] [Related]
16. Atx regulates skeletal muscle regeneration via LPAR1 and promotes hypertrophy.
Ray R; Sinha S; Aidinis V; Rai V
Cell Rep; 2021 Mar; 34(9):108809. PubMed ID: 33657371
[TBL] [Abstract][Full Text] [Related]
17. Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.
Alioli C; Demesmay L; Peyruchaud O; Machuca-Gayet I
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408784
[TBL] [Abstract][Full Text] [Related]
18. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
Schmid R; Wolf K; Robering JW; Strauß S; Strissel PL; Strick R; Rübner M; Fasching PA; Horch RE; Kremer AE; Boos AM; Weigand A
BMC Cancer; 2018 Dec; 18(1):1273. PubMed ID: 30567518
[TBL] [Abstract][Full Text] [Related]
19. The significance of the altered expression of lysophosphatidic acid receptors, autotaxin and phospholipase A2 as the potential biomarkers in type 1 endometrial cancer biology.
Wasniewski T; Woclawek-Potocka I; Boruszewska D; Kowalczyk-Zieba I; Sinderewicz E; Grycmacher K
Oncol Rep; 2015 Nov; 34(5):2760-7. PubMed ID: 26327335
[TBL] [Abstract][Full Text] [Related]
20. Autotaxin and chronic inflammatory diseases.
Magkrioti C; Galaris A; Kanellopoulou P; Stylianaki EA; Kaffe E; Aidinis V
J Autoimmun; 2019 Nov; 104():102327. PubMed ID: 31471142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
